CannTrust Holdings Inc (TRST) Receives a Buy from Canaccord Genuity

By Ryan Adsit

Wall Street analyst has provided a review for the NA company yesterday, but retained the same rating on the stock. Analyst Derek Dley from Canaccord Genuity rated CannTrust Holdings Inc (CNQX: TRST) a Buy, setting a C$13 price target.

Dley commented:

“We are reiterating our SPECULATIVE BUY rating and increasing our target price to C$13.00 (from C$11.00) as we have adjusted our estimates to reflect recent industry developments.”

According to TipRanks.com, Dley is ranked #432 out of 4875 analysts.

CannTrust Holdings Inc has an analyst consensus of Strong Buy, with a price target consensus of C$16.

CannTrust Holdings, Inc. engages in the production and sale of medical cannabis through its subsidiary, CannTrust Inc. The company was founded by Norman Paul on March 16, 2015 and is headquartered in Vaughan, Canada.

The company’s shares closed on Friday at C$10.39.